Alcon Inc. reports developments in eye care through its Surgical and Vision Care businesses. Company news commonly covers quarterly results, constant-currency sales trends, product-launch momentum and portfolio updates across cataract and vitreoretinal surgical systems, intraocular lenses, contact lenses, lens-care products and ocular health.
Recurring updates also include launches and milestones for products such as Clareon, PanOptix, Vivity, TOTAL30, Precision7, Tryptyr and Unity, along with annual general meeting items, board elections, compensation votes, dividends, share repurchase authorizations, acquisitions, integration costs, R&D spending and other governance or capital-allocation actions.
Alcon (SIX/NYSE: ALC) will showcase its latest innovations at the American Academy of Ophthalmology (AAO) 2024 annual meeting. Key highlights include:
- The Voyager DSLT, a new first-line laser therapy for glaucoma patients
- New handheld gas delivery systems, UNIFEYE and UNIPEXY, for retina surgeons
- Pivotal data presentation for AR-15512 (acoltremon 0.003%), a dry eye treatment candidate under FDA review
Alcon's booth #4008 will offer hands-on demonstrations of these technologies. The company emphasizes its focus on improving patient outcomes and enhancing surgical efficiency. New clinical data on Alcon's surgical products will also be presented at the conference.
Alcon (ALC) reported strong Q2 2024 results with record sales of $2.5 billion, up 3% (6% constant currency). Key highlights include:
- Diluted EPS of $0.45, up 32% (47% cc)
- Core diluted EPS of $0.74, up 7% (15% cc)
- H1 2024 cash from operations of $871 million
- Free cash flow of $667 million, up 253%
Growth was driven by robust demand for innovative products, balanced geographic footprint, and strong execution. Surgical sales increased 3% (6% cc) to $1.4 billion, with strength in international markets. Vision Care sales grew 4% (6% cc) to $1.1 billion, led by contact lenses. The company maintained its 2024 outlook, projecting 7-9% constant currency sales growth and core diluted EPS of $3.00-$3.10.
Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received U.S. FDA 510(k) clearance. These systems are the first innovations from Alcon's Unity portfolio, aimed at transforming surgical procedures in ophthalmology. Alcon plans to gather real-world user feedback in the U.S. before a broad commercialization in 2025. The Unity systems are set to replace Alcon's current leading systems and introduce significant workflow efficiencies. Regulatory submissions will continue globally, with a CE Mark expected in early 2025.
Alcon reported strong first-quarter 2024 financial results, with sales reaching $2.4 billion, a 5% increase (7% constant currency). Diluted EPS rose 43% to $0.50, while core diluted EPS improved by 11% to $0.78. The company saw significant growth in its Surgical and Vision Care segments, particularly in innovative contact lenses, which achieved record sales. Operating income rose to $368 million, with a 15.1% operating margin. Cash from operations jumped to $341 million, with free cash flow at $229 million, a $248 million year-over-year increase. A dividend of CHF 0.24 per share was approved. The company's 2024 outlook remains optimistic, maintaining sales and core EPS guidance.
Alcon Inc. announced the successful approval of all proposed resolutions at its 2024 Annual General Meeting. This includes the approval of a dividend of CHF 0.24 per share, re-election of F. Michael Ball as Chair of the Board of Directors, approval of the Board and Executive Committee compensation, and acceptance of financial reports. Shareholders also re-elected other members of the Board and committees, granted discharge to Board and Executive Committee members, and re-elected auditors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.